Search
Close this search box.

HIV Management Guide for Clinical Care

HIV Management Guide for Clinical Care

Search
Close this search box.

Co-infections

Management > Co-infections > References

Sections

Sections

References

  1. Grebel J, Raffa JD, Lai C, et al. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can J Gastroenterol 2007;21:447–51.
  2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
  3. World Health Organisation. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. Geneva: WHO, 2016.
  4. Van de Laar TJW, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007;196:230-8.
  5. Danta M, Brown D, Bhagani S, et al; HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983-91.
  6. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999;170:220-1.
  7. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2023. Hepatitis C. Sydney: Kirby Institute, UNSW Sydney, 2023. https://www.kirby.unsw.edu.au/research/reports/asr2023 (accessed Jun 2024)
  8. Grebely J, Raff a JD, Lai C, Krajden M, Conway B, Tyndall MW. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Canadian Journal of Gastroenterology 2007;21:447-51.
  9. Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995;14:949-53.
  10. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5.
  11. Rockstroh JK, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996;91:2563-8.
  12. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001;183:134-7.
  13. Sulkowski MS, Mehta SH, Torbenson MS, et al. Rapid fibrosis progression among HIV/ hepatitis C virus-co-infected adults. AIDS 2007;21:2209-16.
  14. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of co-infection on survival. Clin Infect Dis 1999;29:150-4.
  15. Gastroenterological Society of Australia. Australian recommendations for the management of hepatitis C virus infection: a consensus statement (2022). GESA 2020. https://hepcguidelines.org.au/the-epidemiology-of-hcv-in-australia/ (accessed Jun 2024)
  16. Sherman KE, Rouster SD, Chung RT, et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
  17. Maheshwari A, Thuluvath PJ. Management of acute hepatitis C. Clin Liver Dis 2010;14:169–76.
  18. European Association For the Study Of The Liver. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol 2020.
  19. Bhattacharya D, Aronsohn A, Price J, Lo Re III V et al. Hepatitis C guidance 2023 update: American association for the study of liver diseases – infectious diseases society of America recommendations for testing, managing, and treating hepatitis c virus infection. Clin Infect Dis 2023.
  20. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005.
  21. Kemp W, Levy M, Weltman M, Lubel J. Australian Liver Association (ALA) expert consensus recommendations for the use of transient elastography in chronic viral hepatitis. J Gastroenterol Hepatol 2015.
  22. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VII Faculty. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022.
  23. Kaplan DE, Ripoll C, Thiele M, Fortune BE, Simonetto D, Garcia-Tsao G, Bosch J. AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatol 2024.
  24. Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 2019.
  25. Gane E, de Ledinghen V, Dylla de, et al. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in phase 2 and 3 clinical trials. J Viral Hep 2021.
  26. Sulkowski M, Feld JJ, Reau NS, et al. Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination. J Hepatol 2021.
  27. Ren X-D, Fu X, He Y-Q, Li C-Y, Guo M, Qiao M. Safety and efficacy of sofosbuvir-velpatasvir: a meta-analysis. Medicine 2022.
  28. Xu H-Q, Wang C-G, Xiao P, Gao Y-H. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C patients: a systematic review and meta-analysis. J Clin Transl Hepatol 2020.
  29. Xie J, Xu B, Wei L, Huang C, Liu W. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis c virus infection salvage therapy in the real world: a systematic review and meta-analysis. Infect Dis Ther 2022.
  30. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de Martino M, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for H-V-1. BMJ 1998.
  31. Serper M, Evon DM, Stewart PW, et al. Medication non-adherence in a prospective, multi-center cohort treated with hepatitis C direct-acting antivirals. J Gen Intern Med 2020.
  32. Akiyama MJ, Norton BI, Arnsten JH, Agyemang I, Heo M, Litwin AH. Intensive models of hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomised controlled trial. Ann Intern Med 2019.
  33. Cunningham EB, Amin J, Feld JJ, et al. Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study. Int J Drug Policy 2018.

Developing a sustainable HIV, Viral Hepatitis and Sexual Health Workforce

Information

About ASHMFeedback
Glossary of TermsPrivacy Policy
AcknowledgementsDisclosure Statements

Acknowledgement of Country

We pay our respects to the Aboriginal and Torres Strait Islander peoples of the past, present, and future, including the Gadigal peoples (Sydney office), the Turrbal and Jagera/Yuggera peoples (Brisbane office), and all First Nations people of the nations where we live and work.

ASHM Health | ABN 48 264 545 457 | CFN 17788 | Copyright © 2024 ASHM

Scroll to Top